Special Issues

Recent Advances and Future Trends in Cancer and Infectious Diseases
Editor: Waqas Nawaz

Submission Deadline: 30 November 2023 (Status: Open)

Special Issue Editor

Dr. Waqas Nawaz      Email
Maisonneuve-Rosemont Hospital, University of Montreal, Quebec, Canada
Interests: immunology; nanotechnology; virology; tumor biology

Special Issue Information

Dear Colleagues,

Cancer and infectious diseases continue to be a major health challenge worldwide. Recent research is focused on developing new therapies and approaches to prevent, detect, and treat these diseases. Nanotechnology has the potential to innovate cancer and infectious disease treatment due to its capacity for targeted drug delivery and imaging. Researchers are developing nanoscale devices that can deliver drugs directly to cancer cells or infected cells, increasing treatment effectiveness while minimizing side effects. Similarly, Immunotherapy is a promising approach to treat cancer. It harnesses body's immune system to fight cancer cells. There are several types of immunotherapies, including immune checkpoint inhibitors, adoptive cell transfer, and cancer vaccines. Researchers are continuing to develop new immunotherapy strategies that are more effective and have fewer side effects.

This Special Issue aims to describe the state-of-the-art treatment as well as the remaining clinical and molecular obstacles. Furthermore, it seeks to identify potential avenues of future treatment and means to improve outcomes for patients with cancer and infectious diseases.

Our overall goal is to collect cutting-edge preclinical research and review to achieve the best possible outcomes for in field researchers and interested readers. This Special Issue shall encompass articles on new therapies to diagnose and treat tumor and other infectious diseases, with a special emphasize on nanotechnologies and immunotherapy approaches.

Waqas Nawaz
Guest Editor


cancer; infectious diseases; nanotechnology; neurological disorders; immunotherapies

Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://www.biolifesas.org/journalx_brha/authorLogOn.action by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. Submitted manuscripts should be well formatted in good English.

Sort by Default Latest Most read  
Please wait a minute...
  • Select all
  • Article
    Cheng Chang, Lili Zhang, Bin Fang, Yaoyao Miao, Zhenlin Yang
    Journal of Biological Regulators and Homeostatic Agents. 2023, 37(7): 3857-3867. https://doi.org/10.23812/j.biol.regul.homeost.agents.20233707.380
    Download PDF (26) HTML (0)   Knowledge map   Save

    Background: Rutin has gained considerable attention in cancer research due to its potential anti-tumor effects. However, the low bioavailability of rutin effect its effectiveness in tumor treatment. Thus, the ion gel method synthesized the rutin-chitosan nanoconjugates in this study. Its anti-tumor effects were evaluated in a xenograft tumor in nude mice, and the underlying mechanisms were explored using transcriptome sequencing.

    Methods: In vitro release test of rutin was carried out using the drug release experiment. The anti-tumor effect of rutin-chitosan nanoconjugates was investigated using a xenograft mouse model. Further studies on rutin targets screened by the transcriptomic analysis were conducted.

    Results: It was proved that rutin-chitosan nanoconjugates had good drug loading, encapsulation rate, and slow-release effect. In vivo experiments showed that compared with free rutin, rutin-chitosan nanoconjugates compound had stronger anti-proliferation and pro-apoptotic effects on transplanted tumors of triple-negative breast cancer (TNBC) cells in nude mice. The sequencing, qRT-PCR and western blot results showed that the mRNA and protein levels of Rasgrp3, Flt4 and Vegfd were significantly decreased in the rutin-chitosan nanoconjugates group.

    Conclusions: Rutin-chitosan nanoconjugates may therefore serve as a new therapeutic agent for breast cancer treatment. This opens a new avenue for the development and use of anti-tumor drugs.